Incretin Atlas·MoleculesTrialsOutcomesTimelinePipelineAboutMedical Adviser's Group
Incretin Atlas › Molecules › Berobenatide (MET-097i)

Berobenatide (MET-097i)

GLP-1 (ultra-long-acting, monthly) · s.c. monthly · Pfizer (Metsera)

Data cut 12 November 2026 · page built 16 November 2026 · 0 trial arms · 0 trials with results · 13 registered trials · see on the pipeline board

Summary

Also known as
Metsera (Pfizer)
Mechanism
GLP-1 (ultra-long-acting, monthly)
Route
s.c. monthly
Company
Pfizer (Metsera)
Highest development stage
phase 3
Status (as of data cut)
Phase 3 started 2026 (monthly dosing); phase 2b VESPER reported 2025 verify
Next milestone
Phase 3; combination with amylin MET-233i

Sources for the status

Indications: regulatory and evidence status

IndicationCodeStatusEvidence
Obesity2 phase 3 ongoingPhase 3 ongoing (monthly dosing)Phase 3
T2D0 no data
CV outcomes0 no data
CKD0 no data
HFpEF0 no data
MASH0 no data
Sleep apnoea2 phase 3 ongoingPhase 3 ongoing
Knee OA0 no data
Alzheimer's0 no data

4 = approved / in a label (FDA, EMA or NMPA), 3 = positive phase 3, 2 = phase 3 ongoing or completed without public results, 1 = phase 2 or signal only, 0 = no data, −1 = negative phase 3/4. L = label, P = PubMed, T = registry.

Trial arms: weight, HbA1c and tolerability

No trial arms with extracted efficacy or tolerability data yet.

Registered trials (13)

From ClinicalTrials.gov and the atlas registry sweep; phase 3 and outcome trials first.

TrialIndicationPhaseStatusStart → primary completionnResultRegistry
VESPER-SUI
The Purpose of This Study is to Learn About the Safety and Effectiveness of Berobenatide in Women With Urine Leakage and With Obesity or Overweight
ObesityPhase 3not yet recruiting2026-11 → 2028-10900not yet recruitingNCT07932925
VESPER-JW
A Study to Learn About Safety and Effects of Once-weekly Treatment With Berobenatide in Adults With Obesity Disease in Japan (VESPER-JW)
ObesityPhase 3recruiting2026-10 → 2029-03180recruitingNCT07794761
NCT07874633 · China
A Study to Learn About the Study Medicine Called PF-08653944 Taken Once-Monthly Compared to Placebo in Chinese Adults With Overweight or Obesity
ObesityPhase 3recruiting2026-10 → 2028-06432recruitingNCT07874633
VESPER-OSA 2
A Study to Learn About the Monthly Dosing Study Medicine Called Berobenatide in Adults With Breathing Problems During Sleep and Overweight or Obesity Who Do Not Use a Breathing Machine (PAP) (VESPER-OSA 2)
Sleep apnoeaPhase 3recruiting2026-10 → 2028-06258recruitingNCT07881757
VESPER-OA 2
A Study to Learn About Berobenatide Given Once Weekly in Adults With Knee Osteoarthritis and Overweight or Obesity With or Without Type 2 Diabetes (VESPER-OA 2)
Knee OAPhase 3recruiting2026-10 → 2028-08756recruitingNCT07915609
VESPER-OA 1
A Study to Learn About Study Medicine Called Berobenatide in Adults With Knee Pain and Overweight or Obesity (VESPER-OA 1)
Knee OAPhase 3recruiting2026-10 → 2028-08656recruitingNCT07919678
NCT07792954 · China
A Study to Learn About the Study Medicine Called PF-08653944 Taken Once-Weekly Compared to Placebo in Chinese Adults With Overweight or Obesity
ObesityPhase 3recruiting2026-09 → 2028-03300recruitingNCT07792954
VESPER-JM
A Study to Learn About Safety and Effects of Once-monthly Treatment With Berobenatide in Adults With Obesity Disease in Japan (VESPER-JM)
ObesityPhase 3recruiting2026-09 → 2029-02197recruitingNCT07794774
VESPER-OSA 1
A Study to Learn About the Monthly Dosing Study Medicine Called Berobenatide in Adults With Breathing Problems During Sleep and Overweight or Obesity Who Use a Breathing Machine (PAP) (VESPER-OSA 1)
Sleep apnoeaPhase 3recruiting2026-09 → 2028-04258recruitingNCT07823608
VESPER-SWITCH
A Study to Learn About Switching to a Monthly Study Medicine Called Berobenatide (PF-08653944) to Help Keep Weight Off in People With Overweight or Obesity
ObesityPhase 3recruiting2026-09 → 2028-02660recruitingNCT07845500
VESPER-6
A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or Obesity
ObesityPhase 3recruiting2026-06 → 2028-05954recruitingNCT07595549
NCT07400653
A Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D)
ObesityPhase 3active not recruiting2026-02 → 2027-101078active not recruitingNCT07400653
VESPER-4
Efficacy and Safety of MET097 Once-Weekly in People With Overweight or Obesity
ObesityPhase 3active not recruiting2025-12 → 2027-093578active not recruitingNCT07311850

Primary sources

No source recorded.

How to cite this page

Medical Adviser's Group. Incretin Atlas: Berobenatide (MET-097i). Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/berobenatide/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.

Cite the primary publication for any single result; every value above links to it.